TransMedics Group, Inc. (NASDAQ:TMDX) Shares Sold by Arcadia Investment Management Corp MI

Arcadia Investment Management Corp MI lessened its holdings in TransMedics Group, Inc. (NASDAQ:TMDX) by 33.3% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 738 shares of the company’s stock after selling 369 shares during the quarter. Arcadia Investment Management Corp MI’s holdings in TransMedics Group were worth $111,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Vanguard Group Inc. lifted its position in shares of TransMedics Group by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 1,889,094 shares of the company’s stock worth $139,680,000 after buying an additional 23,979 shares during the last quarter. Eventide Asset Management LLC lifted its position in TransMedics Group by 7.4% in the fourth quarter. Eventide Asset Management LLC now owns 994,240 shares of the company’s stock valued at $78,475,000 after acquiring an additional 68,884 shares during the last quarter. First Light Asset Management LLC boosted its stake in TransMedics Group by 22.0% in the fourth quarter. First Light Asset Management LLC now owns 754,317 shares of the company’s stock valued at $59,538,000 after acquiring an additional 136,217 shares in the last quarter. Allspring Global Investments Holdings LLC grew its holdings in shares of TransMedics Group by 3.1% during the first quarter. Allspring Global Investments Holdings LLC now owns 730,010 shares of the company’s stock worth $53,977,000 after purchasing an additional 21,737 shares during the last quarter. Finally, Wasatch Advisors LP purchased a new position in shares of TransMedics Group during the first quarter worth about $32,162,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Stock Performance

Shares of NASDAQ:TMDX traded down $4.42 during midday trading on Friday, hitting $138.96. The stock had a trading volume of 257,599 shares, compared to its average volume of 763,010. The company has a market capitalization of $4.58 billion, a PE ratio of -421.72 and a beta of 1.99. TransMedics Group, Inc. has a 1 year low of $36.42 and a 1 year high of $177.37. The stock has a 50 day moving average price of $155.04 and a two-hundred day moving average price of $123.98. The company has a current ratio of 9.37, a quick ratio of 8.48 and a debt-to-equity ratio of 2.67.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $0.14. TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. The company had revenue of $114.30 million for the quarter, compared to analysts’ expectations of $98.84 million. During the same quarter in the previous year, the firm posted ($0.03) EPS. The firm’s quarterly revenue was up 117.7% on a year-over-year basis. As a group, equities analysts predict that TransMedics Group, Inc. will post 1.2 earnings per share for the current fiscal year.

Insider Buying and Selling at TransMedics Group

In other news, insider Nicholas Corcoran sold 10,000 shares of the company’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $176.02, for a total transaction of $1,760,200.00. Following the transaction, the insider now directly owns 21,105 shares of the company’s stock, valued at approximately $3,714,902.10. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other TransMedics Group news, insider Nicholas Corcoran sold 10,000 shares of the company’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $176.02, for a total value of $1,760,200.00. Following the sale, the insider now owns 21,105 shares of the company’s stock, valued at $3,714,902.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director James R. Tobin sold 20,000 shares of the firm’s stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $159.33, for a total value of $3,186,600.00. Following the completion of the transaction, the director now owns 173,146 shares of the company’s stock, valued at approximately $27,587,352.18. The disclosure for this sale can be found here. Over the last quarter, insiders sold 61,247 shares of company stock valued at $9,551,089. 7.00% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on TMDX. Cantor Fitzgerald started coverage on TransMedics Group in a research report on Thursday, June 6th. They issued an “overweight” rating and a $161.00 target price for the company. Canaccord Genuity Group raised their target price on shares of TransMedics Group from $117.00 to $169.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st. Morgan Stanley upped their price target on shares of TransMedics Group from $104.00 to $145.00 and gave the company an “equal weight” rating in a research report on Monday, July 15th. TD Cowen lifted their price objective on shares of TransMedics Group from $130.00 to $175.00 and gave the company a “buy” rating in a research note on Friday, June 7th. Finally, Stephens increased their target price on shares of TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $171.44.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.